The Top 3 Artificial Intelligence (AI) Chip Stocks to Buy With $50,000 in 2026
Over the last few years, technology investors have witnessed unprecedented sums poured into artificial intelligence (AI) infrastructure. Hyperscalers…
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the…
3 E Network Signed a Master Services Agreement with Orka Technologies to Develop a 26MW AI Data Center in Finland
HONG KONG, Dec. 15, 2025 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company”…
The Biggest Risk to Your Portfolio Isn’t Missing AI — It’s Holding These 2 Stocks When the Hype Fades
CoreWeave now pays roughly six times its gross profit just to service interest on its ever-growing debt load.…
Meta’s Chief AI Scientist is leaving the company after 12 years
One of Meta’s top AI researchers, Yann LeCun, is leaving after 12 years with the company to found…
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…
D-Wave Quantum (QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference
LOS ANGELES, CA – September 17, 2025 (NEWMEDIAWIRE) – D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or “The Company”),…
Kinetic Wins State Approvals of $156 Million in BEAD Grants to Expand Multi-Gig Fiber Broadband
Almost 52,000 rural homes and businesses in four states will get access to fiber connections LITTLE ROCK, Ark.,…
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BioXcel Therapeutics BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation…
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
BioXcel Therapeutics Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug.…